Strong H1 2026 results driven by biosimilars and new launches led to 5% net sales growth and 15% core EBITDA increase. Guidance for 2026 is reaffirmed, with robust pipeline expansion, regulatory milestones, and major US litigation resolved, supporting confidence in future growth.Based on Sandoz Gro…
H1 2026 saw 5% net sales growth at constant currencies, driven by biosimilars, which now make up 33% of sales. Core EBITDA margin expanded to 20.9%, and North America led with 47% biosimilar growth. Full-year guidance for sales and margin expansion is confirmed.Original document: Sandoz Group Ltd…
Net sales grew 5% at constant currencies to USD 5.8 billion, led by biosimilars up 20% and now 33% of sales. Core EBITDA margin rose to 20.9%, while legal and restructuring costs weighed on IFRS net income. Full-year guidance is confirmed, with strong pipeline and new launches ahead.Original docume…
Strong H1 2026 results driven by 20% biosimilars growth and robust launches, with net sales up 5% at constant currencies and core EBITDA margin expanding to 20.9%. Full-year guidance is confirmed, supported by a strengthened pipeline and solid cash flow.Original document: Sandoz Group Ltd [SDZ] Sli…
President Donald Trump has said generic drug manufacturers must move production to the United States or face a 100% import tariff from August 2028, with the levy set to rise to 200% in August 2029. The proposal is aimed at bringing more generic pharmaceutical manufacturing onshore, but it could pla…
Sandoz Group AG / Key word(s): PersonnelSandoz announces key leadership changes15-Jul-2026 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing…
Sandoz Group AG/ Key word(s): Regulatory AdmissionSandoz moves up Swiss equity rankings to join premier Swiss Market Index09.07.2026 / 07:00 CET/CESTMEDIA RELEASEBasel, 9 July 2026 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in affordable medicines, today announces that it will be included in…
The U.S. Food and Drug Administration has agreed to review Chinese generics drugmaker Hybio Pharmaceutical's SZSE:300199 two experimental generic tirzepatide GLP-1s that, if approved, would rival obesity and diabetes drugs made by Eli Lilly NYSE:LLY.
The U.S. Food and Drug Administration has agreed to review Swiss generics drugmaker Sandoz's SIX:SDZ two generic tirzepatide GLP-1s that, if approved, would rival obesity drugs made by Eli Lilly NYSE:LLY.With Eli Lilly's tirzepatide patent running out in 2036 in the U.S., makers of alternative drug…
Sandoz Group AG SIX:SDZ:
